Share this link via:
The Global Angina Pectoris Drugs Market size was valued at USD 11.61 Billion in 2023 and is projected to grow at a CAGR of 4.3% from 2024 to 2032.
The rising frequency of cardiovascular illnesses all over the planet is one of the elements moving the worldwide market for angina pectoris drugs. Since cardiovascular illnesses rank among the main sources of death around the world, there is a more prominent requirement for proficient treatments. Transdermal fixes and supported discharge details are two instances of novel medication conveyance innovations that are working on the viability and consistence of drugs for angina pectoris.
The market is significantly affected by the growing geriatric populace, which likewise raises the gamble of cardiovascular illnesses in older people. Drug organizations presently get the opportunity to give customized medicines that meet the exceptional necessities of senior people and improve their personal satisfaction because of this segment change. Drug organizations' essential associations and joint efforts with scholastic foundations are likewise impelling the market's development by speeding up the medication revelation process and advancing the production of creative medication details.
Enhancements in cardiology care, progressing innovative work, and an ascent in the quantity of restorative endorsements from administrative bodies, for example, the FDA are likewise driving business sector open doors. Because of the developing number of retail drug stores and patients' penchant to purchase angina drugs from these chains, new business sectors are arising. Drug organizations can make and offer new meds to address the developing interest for angina pectoris treatments welcomed on by the maturing of the worldwide populace.
One of the essential drivers for the worldwide angina pectoris drugs market is the rising occurrence of cardiovascular sicknesses (CVDs) around the world. Stationary ways of life, unfortunate weight control plans, and elevated degrees of stress have prompted an expansion in heart-related conditions, with angina pectoris being a typical side effect of coronary conduit illness (computer aided design). As the populace ages, the vulnerability to heart conditions likewise develops, which fills the interest for viable angina pectoris prescriptions. As indicated by the World Wellbeing Association, CVDs are the main source of death universally, building up the requirement for cutting edge medicines, including drug treatments.
The market is likewise determined by continuous advancements in drug innovative work. New medication conveyance frameworks, upgraded details, and customized medication approaches are making more compelling and designated medicines for angina pectoris. This incorporates the advancement of novel medication classes like calcium channel blockers, beta-blockers, and nitrates, which offer huge upgrades in side effect the executives and patient results. These mechanical headways are decreasing secondary effects and expanding patient consistence, further impelling business sector development.
The shift toward preventive medical services presents huge learning experiences for the angina pectoris drugs market. Expanding mindfulness about heart wellbeing and the significance of early determination has prompted more popularity for drugs that oversee angina as well as forestall its movement. This pattern is supposed to speed up, especially in developing business sectors, where medical care frameworks are improving and populaces are turning out to be more wellbeing cognizant.
Arising economies, especially in Asia-Pacific and Latin America, offer extensive open doors for market development. These districts are seeing an ascent in cardiovascular sickness cases because of urbanization, evolving ways of life, and further developed medical services framework. Besides, legislatures and confidential medical care suppliers are putting resources into extending admittance to medical services, which incorporates therapies for heart conditions like angina pectoris. Drug organizations can take advantage of these developing business sectors by offering reasonable, available medication choices.
High cost remains the most significant restraint to market growth, particularly the newer formulations for angina pectoris. Advanced therapies are invariably expensive and therefore unreachable in low- and middle-income countries. Similarly, even in developed markets, expensive long-term treatment becomes unaffordable for some patients and results in them not adhering to the prescribed medication regimens. This cost barrier restricts overall market potential and underscores the need for cost-effective drug solutions.
Another challenge to the angina pectoris drugs market is side effects from which they are likely to suffer, as well as drug resistance in patients. Effects such as headaches, dizziness, and the feeling of fatigue may de-motivate patients from further continuation of their medicine, thus creating a poor outcome of treatment. Moreover, long-term use of some drugs can lead to reduced efficacy, hence calling for alternative medication treatments. This poses a significant challenge to drug-making companies and highlights the need for further research into these matters.
Modifiable risk factors that contributed to CVD deaths in 2021 include:
The market scope is segmented because of by Drug Class, by Type, by Application.
Based on the Drug Class of the market is segmented into Nitrates, Beta Blockers, Anticoagulants, Anti-Platelets, Calcium Antagonists, Other Drug Classes.
In 2023, beta blockers constituted a 39.2% market share of angina pectoris sales, thus leading the segment. Its increased adoption as a first-line treatment for angina pectoris is one of the key factors driving the segment forward. The growing elderly population and firm-level strategic market moves to increase commercial availability of beta blockers also contribute to this growth factor. These agents are a critical medication option for an aging population due to their effect on reducing heart rate and depressing cardiac muscle contractions.
The projection period will see the anticoagulants market grow at a notable rate. Since most anticoagulant drugs are administered to patients with angina pectoris in a bid to avert blood clots and the subsequent cardiovascular results, the higher number of cases reported for this disease calls for the growth in the market. New oral anticoagulants have revolutionized the market by making safer and more efficient substitutes of traditional warfarin, and this has really paved the way for expansion.
Based on the Type of the market is segmented into Stable Angina, Unstable Angina, Prinz metal Angina, Micro vascular Angina.
Stable angina accounted for 51.8% in revenue in 2023, accounting for the largest share of the angina pectoris medication market. Chronic stable angina is becoming more common, and in approximately half of these, it is the first symptom of ischemic heart disease. Stable angina can also be triggered by variables such as cold weather or physical activity, explaining why this particular market is on the upswing. There are numerous reasons for the stable angina segment's dominance, including public awareness, research and development, and efficient treatment alternatives.
During the forecast period, the unstable angina category will increase at the fastest rate, 5.8%. A key contributing cause to the increasing incidence of cardiovascular diseases (CVDs) is the aging population, along with lifestyle choices such as smoking, poor diets, and lack of exercise. With the increased CVD patient population, the demand for angina pectoris drugs also increased, especially the unstable angina, a more severe form of the disease. The recent improvement in healthcare infrastructure, advanced diagnostic technology and the rising awareness of CVDs have been able to identify unstable angina earlier. Early detection and treatment promote market growth.
By region, Insights into the markets in North America, Europe, Asia-Pacific, Latin America and MEA are provided by the study. North America dominates the angina pectoris drugs market in large part due to the region's well-established healthcare system, increased therapeutic use, and the presence of significant American manufacturers. Angina is the most common manifestation of ischemic heart disease-the number one cause of death and disability in North America. For instance, data published in February 2022 by the Division for Heart Disease and Stroke Prevention of the National Centre for Chronic Disease Prevention and Health Promotion show that ischemic heart disease, the most common heart disease, was responsible for 360,900 deaths in 2019. Approximately 18.2 million people above age 20 have coronary artery disease. About two out of ten deaths due to coronary heart disease occur in people under 65 years of age.
Similarly, an article titled "Ischemic Heart Disease: Non-invasive Imaging Techniques and Findings" published in RSNA (Radiographic) in May 2021 reported that the prevalence of ischemic heart disease currently stands at approximately 18.2 million cases, with an annual incidence of new coronary events about 720,000 cases only in the United States. With the growing rate of heart diseases due to which the incidence of angina pectoris is on the rise, the area would witness a probable increase in demand for angina pectoris medications. The clinical trials are also proliferating and hence the market. For instance, in the United States, there were 23 on-going or recruiting clinical studies involving angina pectoris till April of 2022. Consequently, during this study period, these factors altogether promote the growth of the angina pectoris medication market.
In May 2024, Novartis and AC Health entered a partnership for integrated cardiovascular and cancer care, with the objective of expanding access to innovative medicines in the areas of cancer, cholesterol, and heart failure, as well as empowering patients through this collaborative effort.
In July 2023, Riparian Pharmaceuticals partnered with Pfizer to advance novel cardiovascular programs, granting Pfizer exclusive rights to a preclinical program to support Riparian’s efforts to discover further drug targets for vasoprotection.
The report will cover the qualitative and quantitative data on the global Angina Pectoris Drugs Market. The qualitative data includes latest trends, market players analysis, market drivers, market opportunity, and many others. Also, the report quantitative data includes market size for every region, country, and segments according to your requirements. We can also provide customize report in every industry vertical.
Study Period | 2024-32 |
Base Year | 2023 |
Estimated Forecast Year | 2024-32 |
Growth Rate | CAGR of 4.3% from 2024 to 2032 |
Segmentation | By Drug Class, By Type, By Distribution Channel, By Region |
Unit | USD Billion |
By Drug Class |
|
By Type |
|
By Distribution Channel |
|
By Region |
|
North America accounted for the highest xx% market share in terms of revenue in the Angina Pectoris Drugs market and is expected to expand at a CAGR of xx% during the forecast period. This growth can be attributed to the growing adoption of Angina Pectoris Drugs. The market in APAC is expected to witness significant growth and is expected to register a CAGR of xx% over upcoming years, because of the presence of key Angina Pectoris Drugs companies in economies such as Japan and China.
The objective of the report is to present comprehensive analysis of Global Angina Pectoris Drugs Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language.
Angina Pectoris Drugs Market Report is also available for below Regions and Country Please Ask for that
Angina Pectoris Drugs Market Trends: Market key trends which include Increased Competition and Continuous Innovations Trends:
You'll get the sample you asked for by email. Remember to check your spam folder as well. If you have any further questions or require additional assistance, feel free to let us know via-
+1 724 648 0810 +91 976 407 9503 sales@intellectualmarketinsights.com
20 Apr 2023
Intellectual Market Insights Research © 2025. All rights reserved.
